This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gennari, A. Articles by Conte, P. F. Search for Related Content PubMed PubMed Citation Articles by Gennari, A. Articles by Conte, P. F.

Cardiotoxicity of Epirubicin/Paclitaxel–Containing Regimens: Role of Cardiac Risk Factors

From the Divisione di Oncologia Medica and Farmacologia e Chemioterapia, Dipartimento di Oncologia, Ospedale Santa Chiara e Universita, Pisa; and Servizio di Epidemiologia Clinica e Sperimentazioni Cliniche Controllate, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.

Address reprint requests to Alessandra Gennari, MD, Division of Medical Oncology, University Hospital Santa Chiara, 67, Via Roma, 56126 Pisa, Italy; email a.gennari{at}do.med.unipi.it

PURPOSE: To evaluate the incidence of clinically relevant cardiac toxicity after treatment with epirubicin/paclitaxel-containing regimens in patients with metastatic breast cancer and to identify high-risk patients in whom the benefit of chemotherapy may be negated by the occurrence of congestive heart failure (CHF).

PATIENTS AND METHODS: A total of 105 patients who were referred for epirubicin/paclitaxel treatment were included in this study. Treatment regimens were as follows: (1) epirubicin 90 mg/m² plus paclitaxel 135 to 225 mg/m² over 3 hours (n = 76); and (2) gemcitabine 1,000 mg/m² on days 1 and 4 plus epirubicin/paclitaxel (n = 29). The occurrence of CHF was detected by physical examination, and left ventricular function was evaluated by bidimensional echocardiography to support the diagnosis. Cardiac risk factors examined in this study included age, prior radiotherapy to the chest, hypertension, and diabetes.

RESULTS: No patient experienced CHF while on treatment. Nine patients (9%) developed CHF after cumulative epirubicin doses of 1,080 mg/m² (n = 4), 720 mg/m² (n = 2), 630 mg/m² (n = 1), and 540 mg/m² (n = 2). One of the two patients who developed CHF after a cumulative epirubicin dose of 540 mg/m² had received consolidation with high-dose chemotherapy. Median time to appearance of cardiologic symptoms was 3 months after the end of treatment (range, 3 to 6 months). Overall, the incidence of CHF was 13% and 4% in patients with or without cardiac risk factors, respectively. The cumulative risk of developing CHF was estimated as 7.7% at a cumulative doses of 720 mg/m² and 48.7% at a cumulative dose of 1,080 mg/m².

CONCLUSION: This study shows that the incidence of CHF after an epirubicin/paclitaxel regimen is low up to cumulative epirubicin doses of 990 mg/m², thus allowing the safe administration of this regimen even in patients who received epirubicin in the adjuvant setting. However, the risk of developing CHF increases when a cumulative dose exceeding 990 mg/m² is reached, concomitantly with the presence of an additional cardiac risk factor.

This article has been cited by other articles:

				B. R.J. H. Bird and S. M. Swain Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems Clin. Cancer Res., January 1, 2008; 14(1): 14 - 24. [Abstract] [Full Text] [PDF]

				E. Salvatorelli, P. Menna, L. Gianni, and G. Minotti Defective Taxane Stimulation of Epirubicinol Formation in the Human Heart: Insight into the Cardiac Tolerability of Epirubicin-Taxane Chemotherapies J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 790 - 800. [Abstract] [Full Text] [PDF]

				G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]

				L. M. Schuchter, M. L. Hensley, N. J. Meropol, and E. P. Winer 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., June 15, 2002; 20(12): 2895 - 2903. [Full Text] [PDF]

				S. Fogli, R. Danesi, A. Gennari, S. Donati, P. F. Conte, and M. Del Tacca Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer Ann. Onc., June 1, 2002; 13(6): 919 - 927. [Abstract] [Full Text] [PDF]

				G. Grasselli, L. Vigano, G. Capri, A. Locatelli, E. Tarenzi, C. Spreafico, A. Bertuzzi, A. Giani, C. Materazzo, S. Cresta, et al. Clinical and Pharmacologic Study of the Epirubicin and Paclitaxel Combination in Women With Metastatic Breast Cancer J. Clin. Oncol., April 15, 2001; 19(8): 2222 - 2231. [Abstract] [Full Text] [PDF]